Sharing Responses to Health Canada’s Consultation on Proposed
Amendments to the Patented Medicines Regulations
In May 2017, Federal Minister of Health Jane Philpott, launched a consultation on proposed amendments to the Patented Medicines Regulations that would have significant effects on how patented drug prices are regulated in Canada. The consultation period closed June 28, 2017.
While a summary of comments received in the consultation will be published in the Regulatory Impact Analysis Statement (RIAS) at Canada Gazette Part I in the fall, the submissions will not be shared publicly in their entirety.
To facilitate transparency during this time of unprecedented change, PDCI has volunteered to accumulate the consultation submissions of those individuals and organizations who wish to have their message shared broadly, and PDCI will share on a centrally located webpage to launch on August 23, 2017.
If you or your organization responded to Health Canada’s Consultation on Proposed Amendments to the Patented Medicines Regulations and are interested to share your response with the public and stakeholder community please contact PDCI’s Managing Director, Kaitlyn Proulx at Kaitlyn.Proulx@pdci.ca or (613) 742-8225 ext. 33.